Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28568187 | 0.92 | RAB9A (0.49) | RAB9ANPC1CYP1A2CYP2C19MCL1 | |
| SCHEMBL5707868 | 0.85 | NPC1 (0.55) | RAB9ANPC1CYP1A2CYP2C19TSHR | |
| SCHEMBL9418052 | 0.82 | NPC1 (0.49) | RAB9ANPC1CYP2C19ALDH1A1MEN1 | |
| SCHEMBL11715245 | 0.80 | NPC1 (0.46) | RAB9ANPC1CYP1A2CYP2C19TSHR | |
| SCHEMBL439174 | 0.78 | MAPT (0.70) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL2567453 | 0.76 | MAPT (0.68) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL11623669 | 0.76 | MAPT (0.68) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL7793708 | 0.76 | MAPT (0.68) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL14402606 | 0.76 | MAPT (0.68) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL28018741 | 0.76 | MAPT (0.68) | RAB9ANPC1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485723-B2 | Process for making trisaryl triazine UV absorbers using Lewis acids and reaction promoters | CYTEC TECHNOLOGY CORP. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070015920-A1 | Process for Making Trisaryl Triazine UV Absorbers Using Lewis Acids and Reaction Promoters | GUPTA RAM B | 2007-01-18 | — | — | US | disclosed |
| EP-1131305-B1 | PROCESS FOR PREPARING TRIAZINES USING A COMBINATION OF LEWIS ACIDS WITH REACTION PROMOTERS | CYTEC TECH CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1382599-B1 | 2-(2,4 dihydroxyphenyl)-4,6 bis(3,4-dimethylphenyl)-s-triazine and 2-(2,4-dihydroxyphenyl)4(3,4-dimethylphenyl)-6-(2,3-dimethylphenyl)-s-triazine and derivatives thereof as UV-absorber | CYTEC TECH CORP (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20050165231-A1 | Process for making triazine UV absorbers using Lewis acids and reaction promoters | GUPTA RAM B (US) | 2005-07-28 | — | — | US | disclosed |
| EP-1109792-B1 | PROCESS FOR MAKING 2- (2,4- DIHYDROXYPHENYL) OR 2- (2,4- DIALKOXYPHENYL)- 4,6- BISARYL- 1,3,5- TRIAZINES | CYTEC TECH CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6900314-B2 | Process for making triazine UV absorbers using lewis acids and reaction promoters | CYTEC TECHNOLOGY CORP. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040204585-A1 | Process for making triazine UV absorbers using lewis acids and reaction promoters | GUPTA RAM B (US) | 2004-10-14 | — | — | US | disclosed |
| US-6730785-B2 | COMPRISING LEWIS ACID AND REACTION PROMOTER IN AN AMOUNT SUFFICIENT TO SYNTHESIZE TRIAZINE COMPOUNDS AT LOWER REACTION TEMPERATURES, GREATER YIELDS, OR HIGHER SELECTIVITIES COMPARED TO LEWIS ACID ALONE | CYTEC TECHNOLOGY CORP. | 2004-05-04 | — | — | US | disclosed |
| US-6710177-B2 | REACTING A CYANURIC HALIDE WITH BENZENE COMPOUND | CYTEC TECHNOLOGY CORP. | 2004-03-23 | — | — | US | disclosed |
| EP-1109792-A1 | PROCESS FOR MAKING 2- (2,4- DIHYDROXYPHENYL) OR 2- (2,4- DIALKOXYPHENYL)- 4,6- BISARYL- 1,3,5- TRIAZINES | CYTEC TECHNOLOGY CORP. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6225468-B1 | HEATING AND PRESSURIZING TRIHALO-1,3,5-TRIAZINE WITH PHENOL DERIVATIVE AND BENZENE DERIVATIVE TO IN PRESENCE OF CATALYST FORM ARYL SUBSTITUTED TRIAZINE COMPOUND | CYTEC TECHNOLOGY CORP. | 2001-05-01 | — | — | US | disclosed |
| WO-2000029392-A1 | PROCESS FOR PREPARING TRIAZINES USING A COMBINATION OF LEWIS ACIDS AND REACTION PROMOTERS | CYTEC TECHNOLOGY CORP. (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000014077-A1 | PROCESS FOR MAKING 2- (2,4- DIHYDROXYPHENYL) OR 2- (2,4- DIALKOXYPHENYL)- 4,6- BISARYL- 1,3,5- TRIAZINES | CYTEC TECHNOLOGY CORP. (US) | 2000-03-16 | — | — | WO | disclosed |
| US-5703075-A | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0525123-B1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | UPJOHN CO (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0525123-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES. | UPJOHN CO (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991019707-A2 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0459983-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | PHARMACIA & UPJOHN COMPANY (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990006921-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204585-A1 | Process for making triazine UV absorbers using lewis acids and reaction promoters | TYR, TDO2, CYP4Z1 | RAB9A 3193/4885NPC1 2663/4885CYP1A2 154/4885 |
| US-20050165231-A1 | Process for making triazine UV absorbers using Lewis acids and reaction promoters | TYR, TDO2, CYP4Z1 | RAB9A 3193/4885NPC1 2663/4885CYP1A2 154/4885 |
| US-20070015920-A1 | Process for Making Trisaryl Triazine UV Absorbers Using Lewis Acids and Reaction Promoters | TYR, TDO2, CYP4Z1 | RAB9A 3123/4885NPC1 2701/4885CYP1A2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.